Hepatocellular carcinoma (HCC) is a leading cause of global cancer death. Curative therapy
is not an option for most patients, often because of underlying liver disease. Experience in …

Many patients with hepatocellular carcinoma (HCC) present with advanced disease, not
amenable to curative therapies such as surgery, transplantation or radiofrequency ablation …

Purpose To describe outcomes of prospective trials of stereotactic body radiotherapy (SBRT)
for hepatocellular carcinoma (HCC). Patients and Methods Two trials of SBRT for patients …

BACKGROUND: The objective of this study was to evaluate the efficacy and safety of
stereotactic body radiation therapy (SBRT) as a local salvage treatment after incomplete …

Background. Since 2005, we have treated hepatocellular carcinoma (HCC) with stereotactic
body radiotherapy (SBRT) uniformly at two dose levels, according to baseline liver function …

Background Recent studies using stereotactic body radiotherapy (SBRT) for hepatocellular
carcinoma (HCC) have reported high tumor response and local control. However, the …

PURPOSE: To examine the safety and efficacy of Cyberknife stereotactic body radiation
therapy (SBRT) and its effect on survival in patients of recurrent hepatocellular carcinoma …

Original article breast, gastrointestinal, and urologic tu mors. Survival rates were reported to
be at 36 and 23% after 5 and 10 years. The best rates were reported for breast cancer and …

Purpose To investigate the role of miR-20a in hepatocellular carcinoma (HCC) cell
radioresistance, which may reveal potential strategies to improve treatment. Methods and …

The incidence of hepatocellular carcinoma (HCC) is increasing, and it is currently the
second leading cause of cancer-related death worldwide. Potentially curative treatment …